1 Center for Medical Imaging and Physiology Skåne University Hospital Lund University Lund Sweden.
2 Experimental Cardiovascular Research Unit Clinical Research Center Clinical Sciences Malmö Lund University Malmö Sweden.
J Am Heart Assoc. 2019 Feb 19;8(4):e009874. doi: 10.1161/JAHA.118.009874.
Background When the lectinlike oxidized low-density lipoprotein (ox LDL) receptor-1 ( LOX -1), a scavenger receptor for ox LDL , binds ox LDL , processes leading to endothelial dysfunction and inflammation are promoted. We aimed to study release mechanisms of LOX -1 and how circulating levels of soluble LOX -1 ( sLOX -1) relate to plaque inflammation and future risk for ischemic stroke. Methods and Results Endothelial cells and leukocytes were used to study release of sLOX -1. Plasma levels of sLOX -1 were determined in 4703 participants in the Malmö Diet and Cancer cohort. Incidence of ischemic stroke was monitored. For 202 patients undergoing carotid endarterectomy, levels of sLOX -1 were analyzed in plasma and plaque homogenates and related to plaque inflammation factors. Endothelial cells released sLOX -1 when exposed to ox LDL . A total of 257 subjects experienced stroke during a mean follow-up of 16.5 years. Subjects in the highest tertile of sLOX -1 had a stroke hazard ratio of 1.75 (95% CI, 1.28-2.39) compared with those in the lowest tertile after adjusting for age and sex. The patients undergoing carotid endarterectomy had a significant association between plasma sLOX -1 and the plaque content of sLOX -1 ( r=0.209, P=0.004). Plaques with high levels of sLOX -1 had more ox LDL , proinflammatory cytokines, and matrix metalloproteinases. Conclusions Our findings demonstrate that ox LDL induces the release of sLOX -1 from endothelial cells and that circulating levels of sLOX -1 correlate with carotid plaque inflammation and risk for ischemic stroke. These observations provide clinical support to experimental studies implicating LOX -1 in atherosclerosis and its possible role as target for cardiovascular intervention.
当凝集素样氧化低密度脂蛋白(ox LDL)受体-1(LOX-1),一种氧化 LDL 的清道夫受体,与 ox LDL 结合时,会促进内皮功能障碍和炎症的发生。我们旨在研究 LOX-1 的释放机制以及循环可溶性 LOX-1(sLOX-1)水平与斑块炎症和未来缺血性卒中风险的关系。
使用内皮细胞和白细胞研究 sLOX-1 的释放。在 Malmö Diet and Cancer 队列的 4703 名参与者中测定了 sLOX-1 的血浆水平。监测缺血性卒中的发生。对 202 例行颈动脉内膜切除术的患者,分析了血浆和斑块匀浆中 sLOX-1 的水平,并与斑块炎症因子相关。当暴露于 ox LDL 时,内皮细胞释放 sLOX-1。在平均随访 16.5 年期间,共有 257 名受试者发生卒中。在调整年龄和性别后,sLOX-1 最高三分位组的卒中风险比为 1.75(95%CI,1.28-2.39)。颈动脉内膜切除术患者的血浆 sLOX-1 与斑块中 sLOX-1 的含量之间存在显著相关性(r=0.209,P=0.004)。sLOX-1 水平高的斑块具有更多的 ox LDL、促炎细胞因子和基质金属蛋白酶。
我们的研究结果表明,ox LDL 诱导内皮细胞释放 sLOX-1,而循环 sLOX-1 水平与颈动脉斑块炎症和缺血性卒中风险相关。这些观察结果为实验研究提供了临床支持,表明 LOX-1 在动脉粥样硬化及其作为心血管干预靶点的可能作用中具有重要作用。